Boston Scientific/Medinol dispute
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific wins the latest round in a long-running patent dispute with stent maker Medinol May 5 when a World Intellectual Property Organization arbitration panel ruled that Boston Scientific's Liberté and Taxus Liberté stents do not infringe Medinol patents. Medinol requested the arbitration in 2006 (1"The Gray Sheet" Feb. 27, 2006, In Brief). In 2005, Boston Scientific paid $750 million to settle infringement claims related to its Express and first-generation Taxus stents. Under the settlement, Medinol cannot sue Boston Scientific again for patent infringement, but can through arbitration seek royalties for past and future sales of other stents through 2017. Medinol has the right to appeal the most recent arbitration ruling to another WIPO panel
You may also be interested in...
Stent sparring resumes
Medinol is seeking royalties from past and future sales of Boston Scientific's Liberté and Taxus Liberté paclitaxel-eluting stent based on its assertion that the stent violates several patents. The Israeli firm filed suit with the World Intellectual Property Organization in Geneva on Feb. 21. In Sept. 2005, Boston Scientific agreed to pay its one-time partner $750 mil. to settle a long-running patent infringement suit related to its Express and first-generation Taxus stents (1"The Gray Sheet" Sept. 26, 2005, p. 11). Medinol also is pursuing patent litigation with Guidant...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.